Ceresoli G L相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma

DIADEM 的最终结果，这是一项 II 期研究，旨在研究度伐利尤单抗治疗晚期既往接受过治疗的恶性胸膜间皮瘤的疗效和安全性。

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2022.100644

Canova, S; Ceresoli, G L; Grosso, F; Zucali, P A; Gelsomino, F; Pasello, G; Mencoboni, M; Rulli, E; Galli, F; De Simone, I; Carlucci, L; De Angelis, A; Belletti, M; Bonomi, M; D'Aveni, A; Perrino, M; Bono, F; Cortinovis, D L

发表日期：2022

文献求助收藏

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial

对于既往未接受治疗且不适合铂类化疗的晚期非小细胞肺癌患者，采用节拍式口服长春瑞滨治疗：随机 II 期 Tempo Lung 试验的结果

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2021.100051

Camerini, A; Morabito, A; Montanino, A; Bernabé, R; Grossi, F; Ramlau, R; Ciuleanu, T-E; Ceresoli, G-L; Pasello, G; de Marinis, F; Bosch-Barrera, J; Laundreau, P; Gautier, S; Ta Thanh Minh, C; Kowalski, D

细胞生物学

发表日期：2021

文献求助收藏

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

使用奥希替尼治疗EGFR突变型非小细胞肺癌的疾病进展：新型靶向药物和联合治疗策略

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2021.100280

Di Noia, V; D'Aveni, A; D'Argento, E; Rossi, S; Ghirardelli, P; Bortolotti, L; Vavassori, V; Bria, E; Ceresoli, G L

细胞生物学

发表日期：2021

文献求助收藏

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

关于前列腺癌雄激素剥夺疗法与SARS-CoV-2感染风险之间的关系

期刊:Annals of Oncology

影响因子:65.4

doi:10.1016/j.annonc.2020.06.005

Caffo, O; Zagonel, V; Baldessari, C; Berruti, A; Bortolus, R; Buti, S; Ceresoli, G L; Donini, M; Ermacora, P; Fornarini, G; Fratino, L; Masini, C; Massari, F; Mosca, A; Mucciarini, C; Procopio, G; Tucci, M; Verri, E; Zucali, P; Buttigliero, C

免疫/内分泌

发表日期：2020

文献求助收藏

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

cMET表达在接受EGFR酪氨酸激酶抑制剂治疗的非小细胞肺癌患者中的作用

期刊:Annals of Oncology

影响因子:65.4

doi:10.1093/annonc/mdn240

Zucali P A, Ruiz M G, Giovannetti E, Destro A, Varella-Garcia M, Floor K, Ceresoli G L, Rodriguez J A, Garassino I, Comoglio P, Roncalli M, Santoro A, Giaccone G

细胞生物学

发表日期：2008

文献求助收藏